Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    aoc 1001
Previous Study | Return to List | Next Study

Study of AOC 1001 in Adult Myotonic Dystrophy Type 1 (DM1) Patients (MARINA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05027269
Recruitment Status : Recruiting
First Posted : August 30, 2021
Last Update Posted : December 21, 2021
Sponsor:
Information provided by (Responsible Party):
Avidity Biosciences, Inc.

Brief Summary:

AOC 1001-CS1 is a randomized, double-blind, placebo-controlled, Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple-doses of AOC 1001 Administered Intravenously to Adult Myotonic Dystrophy Type 1 (DM1) patients (MARINA).

Part A is a single dose design with 1 cohort (dose level). In Part A, the patient duration is 6 months as the treatment period is 1 day followed by a 6 month follow-up period.

Part B is a multiple-ascending dose design with 3 cohorts (dose levels). In Part B, the patient duration is 6 months as the treatment period is 3 months followed by a 3 month follow-up period.


Condition or disease Intervention/treatment Phase
DM1 Myotonic Dystrophy 1 Myotonic Dystrophy Myotonic Dystrophy Type 1 (DM1) Dystrophy Myotonic Myotonic Disorders Steinert Disease Myotonic Muscular Dystrophy Drug: AOC 1001 Drug: Placebo Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 44 participants
Allocation: Randomized
Intervention Model: Sequential Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple-Doses of AOC 1001 Administered Intravenously to Adult Myotonic Dystrophy Type 1 (DM1) Patients
Actual Study Start Date : October 28, 2021
Estimated Primary Completion Date : September 2023
Estimated Study Completion Date : September 2023


Arm Intervention/treatment
Experimental: Part A Single Dose: AOC 1001 Dose Level 1
AOC 1001 will be administered once.
Drug: AOC 1001
AOC 1001 will be administered by intravenous (IV) infusion.

Placebo Comparator: Part A Single Dose: Placebo
Saline will be administered once.
Drug: Placebo
Placebo will be administered by intravenous (IV) infusion.

Experimental: Part B Multiple Ascending Dose: AOC 1001 Dose Levels 2-4
AOC 1001 will be administered three times.
Drug: AOC 1001
AOC 1001 will be administered by intravenous (IV) infusion.

Placebo Comparator: Part B Multiple Ascending Dose: Placebo
Saline will be administered three times.
Drug: Placebo
Placebo will be administered by intravenous (IV) infusion.




Primary Outcome Measures :
  1. Frequency of treatment emergent adverse events (TEAEs) [ Time Frame: Through study completion, up to Day 183 ]

Secondary Outcome Measures :
  1. Plasma pharmacokinetic (PK) parameters [ Time Frame: Through study completion, up to Day 183 ]
    Maximum plasma concentration (Cmax)

  2. Plasma pharmacokinetic (PK) parameters [ Time Frame: Through study completion, up to Day 183 ]
    Time to maximum plasma concentration (Tmax)

  3. Plasma pharmacokinetic (PK) parameters [ Time Frame: Through study completion, up to Day 183 ]
    Terminal Half-life (t1/2)

  4. Plasma pharmacokinetic (PK) parameters [ Time Frame: Through study completion, up to Day 183 ]
    Area Under the Concentration-time Curve (AUC)

  5. Urine pharmacokinetic (PK) parameters [ Time Frame: Through study completion, up to Day 183 ]
    fraction excreted (fe) in urine

  6. AOC 1001 levels in muscle tissue [ Time Frame: Through study completion, up to Day 183 ]
  7. Change and percentage change from baseline in DMPK mRNA knockdown [ Time Frame: Through study completion, up to Day 183 ]
  8. Change and percentage change from baseline in Spliceopathy [ Time Frame: Through study completion, up to Day 183 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria:

  • Genetic diagnosis of DM1 (CTG repeat length ≥ 100)
  • Clinician assessed signs of DM1
  • Ability to walk independently (orthoses and ankle braces allowed) for at least 10 meters at screening

Key Exclusion Criteria:

  • Diabetes that is not adequately controlled
  • BMI > 35 kg/m2
  • Uncontrolled hypertension
  • Congenital DM1
  • History of tibialis anterior (TA) biopsy within 3 months of Day 1 or planning to undergo TA biopsies during study period
  • Recently treated with an investigational drug
  • Treatment with anti-myotonic medication within 14 days of Day 1

Note: Other protocol defined Inclusion/Exclusion criteria may apply.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05027269


Contacts
Layout table for location contacts
Contact: Avidity Biosciences, Inc. 858-771-7038 medinfo@aviditybio.com

Locations
Layout table for location information
United States, California
University of California Los Angeles Recruiting
Los Angeles, California, United States, 90095
Stanford University Recruiting
Palo Alto, California, United States, 94304
United States, Colorado
University of Colorado Not yet recruiting
Denver, Colorado, United States, 80045
United States, Florida
University of Florida Recruiting
Gainesville, Florida, United States, 32608
United States, Kansas
Kansas University Medical Center Recruiting
Kansas City, Kansas, United States, 66205
United States, New York
University of Rochester Medical Center Recruiting
Rochester, New York, United States, 14642
United States, Ohio
Ohio State University Recruiting
Columbus, Ohio, United States, 43221
United States, Virginia
Virginia Commonwealth University Recruiting
Richmond, Virginia, United States, 23298
Sponsors and Collaborators
Avidity Biosciences, Inc.
Investigators
Layout table for investigator information
Study Director: Li Tai, MD Avidity Biosciences, Inc.
Additional Information:
Layout table for additonal information
Responsible Party: Avidity Biosciences, Inc.
ClinicalTrials.gov Identifier: NCT05027269    
Other Study ID Numbers: AOC 1001-CS1
First Posted: August 30, 2021    Key Record Dates
Last Update Posted: December 21, 2021
Last Verified: December 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Avidity Biosciences, Inc.:
AOC 1001
DM1
Myotonic Dystrophy 1
Myotonic Dystrophy Type 1 (DM1)
Myotonic Dystrophy
DM
Dystrophy Myotonic
Myotonic Disorders
Steinert Disease
MARINA
Avidity Biosciences
Avidity
Myotonic Muscular Dystrophy
Additional relevant MeSH terms:
Layout table for MeSH terms
Muscular Dystrophies
Myotonic Dystrophy
Myotonic Disorders
Muscular Disorders, Atrophic
Muscular Diseases
Musculoskeletal Diseases
Neuromuscular Diseases
Nervous System Diseases
Genetic Diseases, Inborn
Heredodegenerative Disorders, Nervous System
Neurodegenerative Diseases